Albiglutide

Scientific Overview

Albiglutide (Tanzeum in US, Eperzan in EU) was a recombinant fusion of two tandem GLP-1 (7-36) molecules with human albumin, developed by GSK and FDA-approved 2014. The HARMONY-OUTCOMES trial showed CV event reduction. GSK voluntarily withdrew the product worldwide in 2018 for commercial reasons despite favorable efficacy.

Citations (4)

1. Efficacy and safety of once-weekly GLP-1 receptor agonist albiglutide (HARMONY 2): 52 week primary endpoint results from a randomised, placebo-controlled trial in patients with type 2 diabetes mellitus inadequately controlled with diet and exercisePubMed
2. Efficacy and safety of once-weekly glucagon-like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52-week primary endpoint results from a randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metforminPubMed
3. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trialPubMed
4. Harmony Outcomes: A randomized, double-blind, placebo-controlled trial of the effect of albiglutide on major cardiovascular events in patients with type 2 diabetes mellitus-Rationale, design, and baseline characteristicsPubMed

Dosages listed are common research protocols found in peer-reviewed literature and clinical trials. Individual results and requirements may vary significantly in a research context.

Key Research Benefits

• Weekly dosing
• HbA1c reduction
• CV benefit (HARMONY)

Potential Side Effects

Labs to monitor

Educational context only, not a testing mandate. Any bloodwork decisions belong with your clinician.

• HbA1c: Primary glycemic efficacy marker for incretin therapy.
• Fasting glucose: Tracks glycemic response and hypoglycemia risk in combination therapy.
• Lipid panel / ApoB: Incretin therapy commonly improves atherogenic lipids alongside weight loss.